Azada Ibrahimova1, Lena E Winestone2, Tamara P Miller3,4, Kyle Kettler5, Alix E Seif6, Yuan-Shung Huang7, Caitlin W Elgarten6,7, Regina M Myers6, Brian T Fisher7,8,9, Richard Aplenc6,7,8, Kelly D Getz6,7,8. 1. Department of Pediatrics and Adolescent Medicine, Einstein Healthcare Network Philadelphia, Philadelphia, Pennsylvania, USA. 2. Division of AIBMT, Department of Pediatrics, UCSF Benioff Children's Hospital, San Francisco, California, USA. 3. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. 4. Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA. 5. Drexel University College of Medicine, Philadelphia, Pennsylvania, USA. 6. Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 7. Center for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 8. Perelman School of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 9. Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND: Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group. METHODS: In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis. RESULTS: Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants. CONCLUSIONS: Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.
BACKGROUND: Treatment of infants with acute leukemia remains challenging, especially for acute lymphocytic leukemia (ALL). Infants have shown markedly higher rates of induction mortality compared with noninfants. There are limited data on presentation acuity and supportive care utilization in this age group. METHODS: In retrospective analyses of patients treated for new onset ALL or acute myeloid leukemia (AML) at pediatric hospitals contributing to the Pediatric Health Information System, we compared presentation acuity, induction mortality, and resource utilization in infants relative to noninfants less than 10 years at diagnosis. RESULTS: Analyses included 10 359 children with ALL (405 infants, 9954 noninfants) and 871 AML (189 infants, 682 noninfants). Infants were more likely to present with multisystem organ failure compared to noninfants for both ALL (12% and 1%, PR = 10.8, 95% CI: 7.4, 15.7) and AML (6% vs. 3%; PR = 2.0, 95% CI: 1.0, 3.7). Infants with ALL had higher induction mortality compared to noninfants, even after accounting for differences in anthracycline exposure and presentation acuity (2.7% vs. 0.5%, HR = 2.1, 95% CI: 1.0, 4.8). Conversely, infants and noninfants with AML had similar rates of induction mortality (3.2% vs. 2.1%, HR = 1.2, 95% CI: 0.3, 3.9), which were comparable to rates among infants with ALL. Infants with ALL and AML had greater requirements for blood products, diuretics, supplemental oxygen, and ventilation during induction relative to noninfants. CONCLUSIONS: Infants with leukemia present with higher acuity compared with noninfants. Induction mortality and supportive care requirements for infants with ALL were similar to all children with AML, and significantly higher than those for noninfants with ALL.
Authors: ZoAnn E Dreyer; Joanne M Hilden; Tamekia L Jones; Meenakshi Devidas; Naomi J Winick; Cheryl L Willman; Richard C Harvey; I-Ming Chen; Fred G Behm; Jeanette Pullen; Brent L Wood; Andrew J Carroll; Nyla A Heerema; Carolyn A Felix; Blaine Robinson; Gregory H Reaman; Wanda L Salzer; Stephen P Hunger; William L Carroll; Bruce M Camitta Journal: Pediatr Blood Cancer Date: 2014-11-14 Impact factor: 3.167
Authors: Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: A M Slats; R M Egeler; A van der Does-van den Berg; C Korbijn; K Hählen; W A Kamps; A J P Veerman; C M Zwaan Journal: Leukemia Date: 2005-04 Impact factor: 11.528
Authors: C Prucker; A Attarbaschi; C Peters; M N Dworzak; U Pötschger; C Urban; F-M Fink; B Meister; K Schmitt; O A Haas; H Gadner; G Mann Journal: Leukemia Date: 2009-02-12 Impact factor: 11.528
Authors: Erin M Guest; Richard Aplenc; Lillian Sung; Susana C Raimondi; Betsy A Hirsch; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Jim Wang; Samir B Kahwash; Amy Heerema-McKenney; Soheil Meshinchi; Alan S Gamis Journal: Blood Date: 2017-07-03 Impact factor: 22.113
Authors: Marko Kavcic; Brian T Fisher; Kari Torp; Yimei Li; Yuan-Shung Huang; Alix E Seif; Marijana Vujkovic; Richard Aplenc Journal: Pediatr Blood Cancer Date: 2012-11-28 Impact factor: 3.167
Authors: Rob Pieters; Martin Schrappe; Paola De Lorenzo; Ian Hann; Giulio De Rossi; Maria Felice; Liisa Hovi; Thierry LeBlanc; Tomasz Szczepanski; Alice Ferster; Gritta Janka; Jeffrey Rubnitz; Lewis Silverman; Jan Stary; Myriam Campbell; Chi-Kong Li; Georg Mann; Ram Suppiah; Andrea Biondi; Ajay Vora; Maria Grazia Valsecchi Journal: Lancet Date: 2007-07-21 Impact factor: 79.321